PROTEIN TURNOVER AND ANABOLIC INTERVENTIONS IN AIDS
Project Number5R01DK049393-02
Contact PI/Project LeaderYARASHESKI, KEVIN E
Awardee OrganizationWASHINGTON UNIVERSITY
Description
Abstract Text
DESCRIPTION: Body protein wasting is an important physical and clinical
problem in patients with AIDS. However, the metabolic basis for this
protein wasting is unknown and no acceptable anabolic intervention
currently exists. This project has 3 objectives. First, the
investigator will evaluate the alterations in whole body and skeletal
muscle protein synthesis and breakdown rates that occur in three subject
populations infected with HIV and referred to the ACTU at Washington
University: a) HIV without weight loss or opportunistic infection and
CD4>200; b) HIV with involuntary unexplained weight loss (>10 percent
body weight within previous year) and CD4<200; and c) HIV with weight
loss, non-life-threatening opportunistic infections and CD4 <200.Second,
they will evaluate whether short-term (2 week) treatment with GH or
resistance exercise training increase whole body and skeletal muscle
protein anabolism in patients with HIV, weight loss, and CD4<200. Each
subject will be studied during a two week control period that
immediately precedes the two week treatment period. This short-term
(within subject design) will minimize the potential confounding effects
of different antiviral therapies in these subjects, and permit a rapid
assessment of the potential muscle anabolic effects of the interventions.
Third, they will evaluate whether long-term treatment (eight week) with
either GH or resistance exercise training continues to enhance whole
body and skeletal muscle protein anabolism, and results in increments
in lean body mass, muscle cross-sectional area, and strength in these
patients. Only the most anabolic short-term intervention will be
studied in these long-term experiments. Whole body and skeletal muscle
protein metabolism will be determined using an intravenous infusion of
tracer quantities of stable isotopically labeled amino acids. The
metabolic fate of these tracers is assessed by measuring the appearance
rate of exhaled labeled CO2, their dilution with naturally occurring
leucine and glutamine in the plasma, and their in vivo incorporation rate
into vastus lateralis muscle protein during 12-13 hour tracer infusion.
Alterations in body composition will be assessed with DXA, MRI of thigh
muscle and fat cross-sectional area, and by measuring total body water.
Knee extensor and flexor maximum voluntary muscle strength will be
assessed on an isokinetic dynamometer.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
068552207
UEI
L6NFUM28LQM5
Project Start Date
30-September-1994
Project End Date
31-August-1998
Budget Start Date
01-September-1995
Budget End Date
31-August-1996
Project Funding Information for 1995
Total Funding
$252,991
Direct Costs
$163,925
Indirect Costs
$89,066
Year
Funding IC
FY Total Cost by IC
1995
National Institute of Diabetes and Digestive and Kidney Diseases
$252,991
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DK049393-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DK049393-02
Patents
No Patents information available for 5R01DK049393-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DK049393-02
Clinical Studies
No Clinical Studies information available for 5R01DK049393-02
News and More
Related News Releases
No news release information available for 5R01DK049393-02
History
No Historical information available for 5R01DK049393-02
Similar Projects
No Similar Projects information available for 5R01DK049393-02